Finance

Lists
Q3 2026 earnings • released • EPS miss -63.62% • Revenue beat +8.93%
See results
SRPT:NASDAQ
Sarepta Therapeutics Inc
$17.82
+1.42%
(+0.25) 1D
$17.82
0.00% (0.00)
After hours
Closed: Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SRPT...
Open
$18.77
High
$18.77
Low
$17.52
Mkt. cap
1.88B
Avg. vol.
2.49M
Volume
2.60M
52-wk high
$24.68
52-wk low
$14.68
EPS
-$1.66
Beta
0.45
Shares outstanding
105.63M
No. of employees
835
Open
$18.77
High
$18.77
Low
$17.52
Mkt. cap
1.88B
Avg. vol.
2.49M
Volume
2.60M
52-wk high
$24.68
52-wk low
$14.68
EPS
-$1.66
Beta
0.45
Shares outstanding
105.63M
No. of employees
835
News stories
From web sources and news partners
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
CEODouglas S. Ingram
Employees835
Founded1980
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitesarepta.com
Analyst ratings
Based on 16 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
3
Hold
9
Sell
4
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current $17.82
$38.00 (+113.24%)
Average
$21.77 (+22.17%)
Lowest
$5.00 (-71.94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Sell
Maintained
-
-
11/06/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$25.00
+40.3%
11/06/2026
Kostas Biliouris
Oppenheimer
Buy
Maintained
$35.00
+96.4%
11/06/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$38.00
+113.2%
11/06/2026
Yun Zhong
Wedbush
Buy
Reiterated
$35.00
+96.4%
11/06/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$18.00
+1%
11/05/2026
Biren Amin
Piper Sandler
Hold
Maintained
$20.00
+12.2%
11/06/2026
Mitchell Kapoor
H.C. Wainwright
Sell
Reiterated
$5.00
-71.9%
11/06/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$18.00
+1%
11/06/2026
Ritu Baral
TD Cowen
Hold
Maintained
$17.00
-4.6%
10/21/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
$20.00
+12.2%
10/15/2026
Anupam Rama
J.P. Morgan
Hold
Reiterated
$20.00
+12.2%
09/30/2026
Lachlan Hanbury Brown
William Blair
Hold
Reiterated
-
-
09/28/2026
Gil Blum
Needham
Sell
Maintained
-
-
09/28/2026
Yigal Nochomovitz
Citi
Sell
Maintained
$13.00
-27%
09/27/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Maintained
$19.00
+6.6%
08/10/2026
Eliana Merle
Barclays
Hold
Maintained
$20.00
+12.2%
08/07/2026
Kristen Kluska
Cantor Fitzgerald
Hold
Maintained
$21.00
+17.8%
08/05/2026
Uy Ear
Mizuho Securities
Buy
Maintained
$31.00
+74%
07/10/2026
Andy Chen
Wolfe Research
Buy
Upgraded
$27.00
+51.5%
07/08/2026
Stephen Brozak
WBB Securities
Buy
Maintained
$38.00
+113.2%
03/26/2026
Unknown Analyst
WBB Securities
Buy
Maintained
$38.00
+113.2%
03/26/2026
David Hoang
Deutsche Bank
Sell
Maintained
$14.00
-21.4%
03/26/2026
William Pickering
Bernstein
Hold
Maintained
$20.00
+12.2%
03/25/2026
Joseph Schwartz
Leerink Partners
Hold
Maintained
$15.00
-15.8%
03/25/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$19.00
+6.6%
03/09/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$17.00
-4.6%
02/25/2026
Sami Corwin
William Blair
Hold
Reiterated
-
-
02/26/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.13 / $0.36
-63.62%miss
Revenue / Est. (USD)
381.35M / 350.10M
+8.93%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
399.36M
442.93M
730.80M
401.25M
Cost of goods sold
369.66M
724.04M
262.73M
240.64M
Cost of revenue
369.66M
724.04M
262.73M
240.64M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
91.89M
128.30M
108.95M
107.60M
Operating expense
92.57M
128.97M
109.64M
108.32M
Total operating expenses
462.24M
853.02M
372.37M
348.96M
Operating income
-62.88M
-410.08M
358.43M
52.29M
Other non operating income
-702.00K
-338.00K
1.16M
-246.00K
EBT including unusual items
-194.05M
-278.30M
343.17M
-1.75M
EBT excluding unusual items
-63.90M
-423.20M
344.24M
36.74M
Income tax expense
-14.10M
4.55M
12.22M
3.14M
Effective tax rate
7.27%
-1.64%
3.56%
-179.59%
Other operating expenses
-
-
-
-
Net income
-179.95M
-282.85M
330.96M
-4.89M
Net profit margin
-45.06%
-63.86%
45.29%
-1.22%
Earnings per share
-0.13
-3.58
3.16
0.64
Interest and investment income
7.25M
8.07M
6.36M
6.21M
Interest expense
-7.56M
-20.84M
-21.71M
-21.51M
Net interest expenses
-316.00K
-12.77M
-15.35M
-15.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
-44.43M
-404.83M
369.03M
62.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps